Skip to main content

Advertisement

Table 1 Characteristics of the cohort

From: Methylation profiling of ductal carcinoma in situand its relationship to histopathological features

Feature Pure ductal carcinomain situ(n = 72) Mixed ductal carcinomain situ(n = 10) All ductal carcinomain situ(n = 82)
Age Median, years 54.0 53.0 54.0
  Range, years 29 to 82 42 to 67 29 to 82
  No data 14/69 1/10 15/79
Lesion size Median, mm 32.0 40.0 32.8
  Range, mm 5 to 145 11 to 103 5 to 145
Nuclear grade High 35/72 (48.6%) 4/10 (40%) 39/82 (47.6%)
  Intermediate 31/72 (43.1%) 6/10 (60%) 37/82 (45.1%)
  Low 6/72 (8.3%) 0/10 (0%) 6/82 (7.3%)
Predominant architectural pattern Solid 37/72 (51.4%) 10/10 (100%) 47/82 (57.3%)
  Cribriform 17/72 (23.6%) 0/10 (0%) 17/82 (20.7%)
  Micropapillary 11/72 (15.3%) 0/10 (0%) 11/82 (13.4%)
  Clinging 4/72 (5.6%) 0/10 (0%) 4/82 (4.9%)
  Cancerisation of lobules 2/72 (2.8%) 0/10 (0%) 2/82 (2.4%)
  Papillary 1/72 (1.4%) 0/10 (0%) 1/82 (1.2%)
Comedo necrosis Present 29/72 (40.3%) 6/10 (60%) 35/82 (42.7%)
  Absent 43/72 (59.7%) 4/10 (40%) 47/82 (57.3%)
Estrogen receptor status Positive 48/67 (71.6%) 7/8 (87.5%) 55/75 (73.3%)
  Negative 19/67 (28.4%) 1/8 (12.5%) 20/75 (26.7%)
  No data 5/72 2/10 7/82
Progesterone receptor status Positive 40/67 (59.7%) 3/8 (37.5%) 43/75 (57.3%)
  Negative 27/67 (40.3%) 5/8 (62.5%) 32/75 (42.7%)
  No data 5/72 2/10 7/82
HER2 amplification Amplified 20/67 (29.9%) 2/8 (25%) 22/75 (29.3%)
  Non-amplified 47/67 (70.1%) 6/8 (75%) 53/75 (70.7%)
  No data 5/72 2/10 7/82
Intrinsic subtype Luminal 38/67 (56.7%) 6/8 (75%) 44/75 (58.7%)
  HER2 20/67 (29.9%) 2/8 (25%) 22/75 (29.3%)
  Basal 2/67 (3.0%) 0/8 (0%) 2/75 (2.6%)
  Negative 7/67 (10.4%) 0/8 (0%) 7/75 (9.3%)
  No data 5/72 2/10 7/82